Testing a Combination of DS-8201a and Olaparib in HER2-Expressing Cancers
Phase 1
55
about 5.6 years
18+
5 sites in AZ, FL, MA +2
What this study is about
This trial is testing the safety and best dose of DS-8201a and olaparib, a treatment combination, in people with HER2-positive cancers that have spread or are resistant to platinum chemotherapy. The goal is to determine how well this treatment works and what side effects it causes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Trastuzumab Deruxtecan
- 2.Take Olaparib
- 3.Undergo Biopsy Procedure
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
olaparib, trastuzumab deruxtecan
oral, infusion
Primary: Incidence of adverse events, Maximum tolerated dose/recommended phase 2 dose
Secondary: Clinical benefit rate (CBR), Duration of response (DOR), Objective response rate (ORR), Plasma pharmacokinetic (PK) profiles
biopsy, diagnostic, imaging
Oncology